Recent News

• 02.25.2025 - FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
• 02.25.2025 - FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025
• 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
• 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
• 01.13.2025 - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.13.2025 - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.09.2025 - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.09.2025 - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.09.2025 - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.09.2025 - Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2025 - 8-K Current report
• 12.30.2024 - 4 Statement of changes in beneficial ownership of securities